Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialTony Mok, Nelly Cherciu, Byoung Chul Cho et al.|The Lancet|2019Cited by 3.3k
Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesotheliomaRiki Okita, Keisuke Aoe|Scientific Reports|2024Cited by 3